Sanofi's CEO Paul Hudson revealed that the company utilizes artificial intelligence to assist in progressing drug candidates through development phases. The AI system dispassionately recommends whether drugs should advance, supporting human decision-makers with unbiased input. This approach has been in place at Sanofi for about three years, representing roughly a third of a drug's discovery timeline. Hudson emphasized that AI complements human efforts and does not threaten jobs when combined effectively. This insight was shared during a panel at Davos, highlighting the growing role of AI in pharmaceutical R&D.